

Report Information

More information from: <https://www.marketresearchfuture.com/reports/commercial-pharmaceutical-analytics-market-828>

Commercial Pharmaceutical Analytics Market Research Report—Global Forecast till 2032

Report / Search Code: MRFR/HCIT/0332-CR

Publish Date: December, 2022

[Request Sample](#)

Price	1-user PDF : \$ 4950.0	Site PDF : \$ 3250.0	Enterprise PDF : \$ 7250.0
-------	------------------------	----------------------	----------------------------

Description:

Global Commercial Pharmaceutical Analytics Market Overview

Commercial pharmaceutical analytics Market Size was valued at USD 13.8 Billion in 2022. The commercial pharmaceutical analytics market industry is projected to grow from USD 16.408 Billion in 2023 to USD 65.5414 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18.90% during the forecast period (2023 - 2032). The demand for commercial pharmaceutical analytics is being driven by the expanding use of analytical technologies to streamline business processes. In contrast, it is projected that the market driver would offer substantial development prospects for participants in the commercial pharmaceutical analytics market.

Global Commercial Pharmaceutical Analytics Market Overview

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Commercial Pharmaceutical Analytics Market Trends

- Growing use of new technology and analytical tools to drive the market growth

The pharmaceutical sector may change due to the adoption of cutting-edge technologies and analytical tools that will speed up and improve the efficiency of operations. Predictive analytics based on market research, chemical composition, biological characteristics, and other variables are being performed by pharmaceutical and biopharmaceutical producers with the assistance of a number of techniques, including machine learning (ML), the Internet of Things (IoT), and Artificial Intelligence (AI). Many drug discovery processes can be automated and accelerated using AI techniques, reducing the cost of producing pharmaceuticals. Several significant businesses, including Moderna, Inc. (US), have benefited from AI-based decision-making in rapidly developing COVID-19 vaccines. Researchers can also remotely control or keep an eye on equipment in the lab due to IoT connectivity. These new technologies and analytical tools also guarantee greater quality and compliance by lowering manual errors and variability and advancing dependability and validity more quickly.

Additionally, to effectively manage their consumers and advance the manufacture and distribution of pharmaceutical products, thousands of pharma businesses with a sizable customer base worldwide are working. As a result, there is a demand for commercial pharmaceutical analytics. In 2020, about 45 Americans claimed to have a reasonable amount of faith in pharmaceutical corporations to look out for their best interests.

Furthermore, by providing a range of solutions and services related to overall operations, commercial pharmaceutical analytics services assist pharmaceutical and biopharmaceutical firms in concentrating on their core capabilities. Pharmaceutical businesses are highly interested in outsourcing commercial pharmaceutical analytics services. This results from the increasing quantity of brand-new, innovative, and swiftly evolving therapeutic substances. Thus, driving the commercial pharmaceutical analytics market revenue.

Commercial Pharmaceutical Analytics Market Segment Insights

Commercial Pharmaceutical Analytics Type Insights

The commercial pharmaceutical analytics market segmentation, based on type includes descriptive analytics, predictive analytics and prescriptive analytics. The prescriptive analytics segment dominated the market. The urge to change the future is a component of prescriptive analytics, which comes after predictive analytics. Prescriptive analytics recommends actions and outcomes likely to

increase important pharma business metrics. Prescriptive analytics typically offers insights, including knowledge about potential outcomes, prior results, and available resources, and then suggests a course of action or plan to implement or adjust.

Commercial Pharmaceutical Analytics Application Insights

The commercial pharmaceutical analytics market segmentation, based on application, includes R&D, marketing & sales, supply chain optimization and internal reporting. The R&D category generated the most income. The pharmaceutical industry is adopting pharma analytics for use in research and development to aid in identifying, analyzing, and using research and development data. Data is developed from a range of sources in the healthcare and pharmaceutical businesses, including the R&D process itself, retailers, patients, and parental figures. It will be easier for pharmaceutical companies to find new potential drugs and develop them more swiftly if they utilize this information efficiently.

Commercial Pharmaceutical Analytics Deployment Insights

The commercial pharmaceutical analytics market segmentation, based on deployment, includes on-premise and web-based/cloud-based. The on-premise category generated the most income. The term "on-premises" refers to the full software installation within the company. The user can access this model by remaining within the organization. Small pharmaceutical businesses, organizations, and clinics where the data is relatively low typically use the on-premises option. On-premises models are more advantageous in areas with poor internet connectivity or in rural areas.

Figure 1 Commercial Pharmaceutical Analytics Market, by Deployment, 2022 & 2032 (USD Billion)

Commercial Pharmaceutical Analytics Market, by Deployment, 2022 & 2032
--

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Commercial Pharmaceutical Analytics Components Insights

The commercial pharmaceutical analytics market segmentation, based on components, includes software and services. The software category generated the most income. The development of analytical software and its application in the pharmaceutical sector for streamlining various clinical and administrative processes is a major factor driving the growth of the commercial pharmaceutical analytics market. Large pharmaceutical corporations, small businesses, and clinical settings use analytical software.

Commercial Pharmaceutical Analytics Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American commercial pharmaceutical analytics market area will dominate this market. This is ascribed to the transformation of the pharmaceutical commercial function through the application of commercial pharmaceutical analytical technologies including artificial intelligence (AI), machine learning, data mining, and others.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET SHARE BY REGION 2022 (USD Billion)

COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET SHARE BY REGION 2022

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe commercial pharmaceutical analytics market accounts for the second-largest market share. Throughout the projected period, market growth in the region will be fueled by the region's well-established pharmaceutical industry and the high adoption rate of technologically cutting-edge analytic solutions like descriptive, predictive, and prescriptive analytics to support overall company activities. Further, the German commercial pharmaceutical analytics market held the largest market share, and the UK commercial pharmaceutical analytics market was the fastest growing market in the European region

The Asia-Pacific Commercial pharmaceutical analytics Market is expected to grow at the fastest CAGR from 2023 to 2032. This is a result of factors like expanding healthcare infrastructure, government programmes, and a growing number of patients with chronic illnesses like cancer, arthritis, osteoporosis, chronic renal disease, and cardiac disorders. The Asia-Pacific area is the most popular for outsourcing commercial pharmaceutical analytics services due to the accessibility of technical competence, the lower cost of labour, and the growing acceptance of the newest technologies for convenience of work. Moreover, China's commercial pharmaceutical analytics market held the largest market share, and the Indian commercial pharmaceutical analytics market was the fastest growing market in the Asia-Pacific region.

Commercial Pharmaceutical Analytics Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the commercial pharmaceutical analytics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with

important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, commercial pharmaceutical analytics industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the commercial pharmaceutical analytics industry to benefit clients and increase the market sector. In recent years, the commercial pharmaceutical analytics industry has offered some of the most significant advantages to market. Major players in the commercial pharmaceutical analytics market attempting to increase market demand by investing in research and development operations include TRINITY PHARMA SOLUTIONS, TAKE Solutions Ltd., Statistical Analysis System, SCIO HEALTH ANALYTICS, Northwest Analytics Inc., International Business Machines Corporation, CitiusTech Inc., Wipro, ORACLE and IBM.

A leader in health information technology, CitiusTech is headquartered in Mumbai, India. Healthcare technology services are offered by CitiusTech Inc. The business provides services for developing healthcare applications as well as for implementing and monitoring products and moving data. Consumers are served by CitiusTech. CitiusTech plays a significant and profound role in enabling the future of healthcare by, serving more than 130 healthcare organisations.

The Austin, Texas-based Oracle Corporation is a multinational American company that specialises in computer technology. According to sales and market capitalization, Oracle was the third-largest software firm in the world in 2020. The company sells enterprise software products like human capital management (HCM) software, enterprise performance management (EPM) software, enterprise resource planning (ERP) software, customer relationship management (CRM) software (also known as customer experience), and supply chain management (SCM) software, as well as database software and technology (especially under its own brands).

Key Companies in the commercial pharmaceutical analytics market include

- TRINITY PHARMA SOLUTIONS
- TAKE Solutions Ltd.
- Statistical Analysis System
- SCIO HEALTH ANALYTICS
- Northwest Analytics Inc.
- International Business Machines Corporation
- CitiusTech Inc.
- Wipro
- ORACLE
- IBM

Commercial Pharmaceutical Analytics Industry Developments

March 2022 Danish systems biology and bioinformatics business Intomics was purchased by ZS (US). Intomic's services advance the discovery and development of pharmaceutical drugs by providing comprehensive analysis of biomedical data. The hiring of famous experts has increased ZS's dedication to discovering breakthrough medications for everyone.

January 2022 Brighton Park Capital served as the round's lead investor, helping TheMathCompany (India) raise \$50 million. The start-up's entry into the European and American markets is made possible by the investment. Co. dx, a unique platform, is also being improved.

August 2021 Medical Marketing Economics, LLC (US), a pioneer in pricing, reimbursement, and market access (PRMA) services, was purchased by Indegene. It now has access to a bigger client base, an operations backbone, and several potential for growth into adjacent services thanks to this acquisition.

Commercial Pharmaceutical Analytics Market Segmentation

Commercial Pharmaceutical Analytics Type Outlook (USD Billion, 2018-2032)

- Descriptive Analytics
- Predictive Analytics
- Prescriptive Analytics

Commercial Pharmaceutical Analytics Application Outlook (USD Billion, 2018-2032)

- R&D
- Marketing & Sales
- Supply Chain Optimization
- Internal Reporting

Commercial Pharmaceutical Analytics Deployment Outlook (USD Billion, 2018-2032)

- On-Premise
- Web-Based/Cloud-Based

Commercial Pharmaceutical Analytics Components Outlook (USD Billion, 2018-2032)

- Software
- Services

Commercial Pharmaceutical Analytics Regional Outlook (USD Billion, 2018-2032)

- North America
 - US
 - Canada
- Europe
 - Germany
 - France
 - UK
 - Italy
 - Spain
 - Rest of Europe
- Asia-Pacific
 - China
 - Japan
 - India
 - Australia
 - South Korea
 - Australia
 - Rest of Asia-Pacific
- Rest of the World
 - Middle East
 - Africa
 - Latin America

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVES
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING ADOPTION OF EMERGING TECHNOLOGIES AND ANALYTICAL TOOLS
4.2.2 REGULATION OF R&D PRODUCTIVITY
4.2.3 GROWING TREND OF THE BIG DATA ADVERTISEMENT IN PHARMA SECTOR
4.2.4 INCREASING USAGE OF ANALYTICAL TOOLS IN STREAMLINING BUSINESS PROCESS
4.3 RESTRAINTS
4.3.1 SCARCITY OF LABOR AND HIGH LABOR COST
4.3.2 CONSERVATIVE NATURE OF HEALTHCARE INDUSTRY
4.4 OPPORTUNITY
4.4.1 GROWING TREND OF OUTSOURCING
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 PRODUCT DEVELOPMENT & BUSINESS ACQUISITION (PDBA)
5.1.2 MARKETING AND DISTRIBUTION
5.1.3 CONTRACT MANAGEMENT
5.1.4 CUSTOMER SERVICE & SUPPORT
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS:
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT FROM SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS:
5.2.5 INTENSITY OF RIVALRY:
5.3 COVID-19 IMPACT ANALYSIS
5.3.1 IMPACT ON ADOPTION OF SOFTWARE
5.3.2 IMPACT ON ACCEPTANCE OF CLOUD-BASED TECHNOLOGIES
5.3.3 IMPACT ON KEY PLAYERS
5.3.4 IMPACT ON PRICING
6 GLOBAL COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE
6.1 OVERVIEW
6.2 DESCRIPTIVE ANALYTICS
6.3 PREDICTIVE ANALYTICS
6.4 PRESCRIPTIVE ANALYTICS
7 GLOBAL COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS
7.1 OVERVIEW
7.2 SOFTWARE
7.3 SERVICES
8 GLOBAL COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DATA ANALYTICS
8.3 COMMERCIAL EXCELLENCE
8.4 DATA MANAGEMENT
8.5 R&D
8.6 CLINICAL
9 GLOBAL COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT
9.1 OVERVIEW
9.2 ON-PREMISES
9.3 WEB-BASED/CLOUD-BASED
10 GLOBAL COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY REGION
10.1 OVERVIEW
10.2 AMERICAS
10.2.1 NORTH AMERICA
10.2.1.1 US
10.2.1.2 CANADA
10.2.2 LATIN AMERICA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 GERMANY
10.3.1.2 UK
10.3.1.3 FRANCE
10.3.1.4 ITALY
10.3.1.5 SPAIN
10.3.1.6 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA

- 10.4.6 REST OF ASIA PACIFIC
- 10.5 MIDDLE EAST & AFRICA
 - 10.5.1 MIDDLE EAST
 - 10.5.2 AFRICA
- 11 COMPETITIVE LANDSCAPE
 - 11.1 OVERVIEW
 - 11.2 COMPETITIVE BENCHMARKING
 - 11.3 MAJOR GROWTH STRATEGY IN COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET
 - 11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET
 - 11.5 KEY DEVELOPMENT ANALYSIS
 - 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
 - 11.6.1 PRODUCT APPROVALS AND PRODUCT LAUNCHES
 - 11.6.2 PARTNERSHIP/COLLABORATION/INVESTMENT
 - 11.6.3 BUSINESS EXPANSIONS/AGREEMENTS
 - 11.6.4 MERGERS & ACQUISITIONS
 - 11.7 MAJOR PLAYERS SALES ANALYSIS
 - 11.7.1 SALES & OPERATING INCOME
 - 11.8 MAJOR PLAYERS R&D ANALYSIS
- 12 COMPANY PROFILES
 - 12.1 D CUBE ANALYTICS
 - 12.1.1 COMPANY OVERVIEW
 - 12.1.2 FINANCIAL ANALYSIS
 - 12.1.3 PRODUCTS OFFERED
 - 12.1.4 KEY DEVELOPMENTS
 - 12.1.5 KEY STRATEGIES
 - 12.2 GENPACT
 - 12.2.1 COMPANY OVERVIEW
 - 12.2.2 FINANCIAL OVERVIEW
 - 12.2.3 PRODUCTS OFFERED
 - 12.2.4 KEY DEVELOPMENTS
 - 12.2.5 KEY STRATEGIES
 - 12.3 AUROCHS
 - 12.3.1 COMPANY OVERVIEW
 - 12.3.2 FINANCIAL ANALYSIS
 - 12.3.3 PRODUCTS OFFERED
 - 12.3.4 KEY DEVELOPMENTS
 - 12.3.5 KEY STRATEGIES
 - 12.4 THEMATHCOMPANY
 - 12.4.1 COMPANY OVERVIEW
 - 12.4.2 FINANCIAL ANALYSIS
 - 12.4.3 PRODUCTS OFFERED
 - 12.4.4 KEY DEVELOPMENTS
 - 12.4.5 KEY STRATEGIES
 - 12.5 AXTRIA
 - 12.5.1 COMPANY OVERVIEW
 - 12.5.2 FINANCIAL ANALYSIS
 - 12.5.3 PRODUCTS OFFERED
 - 12.5.4 KEY DEVELOPMENTS
 - 12.5.5 KEY STRATEGIES
 - 12.6 ZS
 - 12.6.1 COMPANY OVERVIEW
 - 12.6.2 FINANCIAL ANALYSIS
 - 12.6.3 PRODUCTS OFFERED
 - 12.6.4 KEY DEVELOPMENTS
 - 12.6.5 KEY STRATEGIES
 - 12.7 INDEGENE
 - 12.7.1 COMPANY OVERVIEW
 - 12.7.2 FINANCIAL ANALYSIS
 - 12.7.3 PRODUCTS OFFERED
 - 12.7.4 KEY DEVELOPMENTS
 - 12.7.5 KEY STRATEGIES
 - 12.8 TIGER ANALYTICS
 - 12.8.1 COMPANY OVERVIEW
 - 12.8.2 FINANCIAL ANALYSIS
 - 12.8.3 PRODUCTS OFFERED
 - 12.8.4 KEY DEVELOPMENTS
 - 12.8.5 KEY STRATEGIES
 - 12.9 BEGHOU CONSULTING
 - 12.9.1 COMPANY OVERVIEW
 - 12.9.2 FINANCIAL ANALYSIS
 - 12.9.3 PRODUCTS OFFERED
 - 12.9.4 KEY DEVELOPMENTS
 - 12.9.5 KEY STRATEGIES
 - 12.10 TACT.AI TECHNOLOGIES, INC.
 - 12.10.1 COMPANY OVERVIEW
 - 12.10.2 FINANCIAL ANALYSIS
 - 12.10.3 PRODUCTS OFFERED
 - 12.10.4 KEY DEVELOPMENTS
 - 12.10.5 KEY STRATEGIES
 - 12.11 ANAPLAN, INC.
 - 12.11.1 COMPANY OVERVIEW
 - 12.11.2 FINANCIAL ANALYSIS
 - 12.11.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
 - 12.11.4 KEY DEVELOPMENTS
 - 12.11.5 KEY STRATEGIES
 - 12.12 IBM
 - 12.12.1 COMPANY OVERVIEW
 - 12.12.2 FINANCIAL OVERVIEW
 - 12.12.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
 - 12.12.4 KEY DEVELOPMENTS
 - 12.12.5 SWOT ANALYSIS
 - 12.12.6 KEY STRATEGIES

12.13 COGNIZANT
12.13.1 COMPANY OVERVIEW
12.13.2 FINANCIAL OVERVIEW
12.13.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.13.4 KEY DEVELOPMENTS
12.13.5 KEY STRATEGIES
12.14 ACCENTURE
12.14.1 COMPANY OVERVIEW
12.14.2 FINANCIAL OVERVIEW
12.14.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.14.4 KEY DEVELOPMENTS
12.14.5 SWOT ANALYSIS
12.14.6 KEY STRATEGIES
12.15 MEDIDATA SOLUTIONS
12.15.1 COMPANY OVERVIEW
12.15.2 FINANCIAL OVERVIEW
12.15.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.15.4 KEY DEVELOPMENTS
12.15.5 KEY STRATEGIES
12.16 CITIUSTECH INC.
12.16.1 COMPANY OVERVIEW
12.16.2 FINANCIAL OVERVIEW
12.16.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.16.4 KEY DEVELOPMENTS
12.16.5 KEY STRATEGIES
12.17 PHARMAACE
12.17.1 COMPANY OVERVIEW
12.17.2 FINANCIAL OVERVIEW
12.17.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.17.4 KEY DEVELOPMENTS
12.17.5 KEY STRATEGIES
12.18 FRACTAL ANALYTICS INC.
12.18.1 COMPANY OVERVIEW
12.18.2 FINANCIAL OVERVIEW
12.18.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.18.4 KEY DEVELOPMENTS
12.18.5 KEY STRATEGIES
12.19 MU SIGMA
12.19.1 COMPANY OVERVIEW
12.19.2 FINANCIAL OVERVIEW
12.19.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.19.4 KEY DEVELOPMENTS
12.19.5 KEY STRATEGIES
12.20 WNS (HOLDINGS) LTD.
12.20.1 COMPANY OVERVIEW
12.20.2 FINANCIAL OVERVIEW
12.20.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.20.4 KEY DEVELOPMENTS
12.20.5 SWOT ANALYSIS
12.20.6 KEY STRATEGIES
12.21 TATA CONSULTANCY SERVICES LIMITED
12.21.1 COMPANY OVERVIEW
12.21.2 FINANCIAL OVERVIEW
12.21.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.21.4 KEY DEVELOPMENTS
12.21.5 SWOT ANALYSIS
12.21.6 KEY STRATEGIES
12.22 WIPRO
12.22.1 COMPANY OVERVIEW
12.22.2 FINANCIAL OVERVIEW
12.22.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.22.4 KEY DEVELOPMENTS
12.22.5 SWOT ANALYSIS
12.22.6 KEY STRATEGIES
12.23 VEEVA SYSTEMS INC.
12.23.1 COMPANY OVERVIEW
12.23.2 FINANCIAL OVERVIEW
12.23.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.23.4 KEY DEVELOPMENTS
12.23.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 4 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, FOR DESCRIPTIVE ANALYTICS, BY REGION, 2018–2030 (USD MILLION)
TABLE 5 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, FOR PREDICTIVE ANALYTICS, BY REGION, 2018–2030 (USD MILLION)
TABLE 6 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, FOR PREDICTIVE ANALYTICS, BY REGION, 2018–2030 (USD MILLION)
TABLE 7 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)
TABLE 8 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, FOR SOFTWARE, BY REGION, 2018–2030 (USD MILLION)
TABLE 9 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, FOR SERVICES, BY REGION, 2018–2030 (USD MILLION)
TABLE 10 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030

(USD MILLION)

TABLE 11 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, FOR DATA ANALYTICS, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, FOR COMMERCIAL EXCELLENCE, BY REGION, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, FOR DATA MANAGEMENT, BY REGION, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, FOR R&D, BY REGION, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, FOR CLINICAL, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, FOR ON-PREMISES, BY REGION, 2018–2030 (USD MILLION)

TABLE 18 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, FOR WEB-BASED/CLOUD-BASED, BY REGION, 2018–2030 (USD MILLION)

TABLE 19 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 20 AMERICAS: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 21 AMERICAS: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 22 AMERICAS: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)

TABLE 23 AMERICAS: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 24 AMERICAS: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)

TABLE 25 NORTH AMERICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 26 NORTH AMERICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 27 NORTH AMERICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)

TABLE 28 NORTH AMERICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 29 NORTH AMERICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)

TABLE 30 US: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 31 US: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)

TABLE 32 US: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 33 US: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)

TABLE 34 CANADA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 35 CANADA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)

TABLE 36 CANADA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 37 CANADA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)

TABLE 38 LATIN AMERICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 39 LATIN AMERICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)

TABLE 40 LATIN AMERICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 41 LATIN AMERICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)

TABLE 42 EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 43 EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 44 EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)

TABLE 45 EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 46 EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)

TABLE 47 WESTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 48 WESTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 49 WESTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)

TABLE 50 WESTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 51 WESTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)

TABLE 52 GERMANY: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 53 GERMANY: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)

TABLE 54 GERMANY: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)

TABLE 55 GERMANY: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)

TABLE 56 UK: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 57 UK: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)

TABLE 58 UK: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 59 UK: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)
TABLE 60 FRANCE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 61 FRANCE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)
TABLE 62 FRANCE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 63 FRANCE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)
TABLE 64 ITALY: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 65 ITALY: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)
TABLE 66 ITALY: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 67 ITALY: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)
TABLE 68 SPAIN: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 69 SPAIN: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)
TABLE 70 SPAIN: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 71 SPAIN: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)
TABLE 72 REST OF WESTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 73 REST OF WESTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)
TABLE 74 REST OF WESTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 75 REST OF WESTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)
TABLE 76 EASTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 77 EASTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)
TABLE 78 EASTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 79 EASTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)
TABLE 80 ASIA PACIFIC: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 81 ASIA PACIFIC: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 82 ASIA PACIFIC: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)
TABLE 83 ASIA PACIFIC: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 84 ASIA PACIFIC: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)
TABLE 85 JAPAN: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 86 JAPAN: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)
TABLE 87 JAPAN: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 88 JAPAN: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)
TABLE 89 CHINA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 90 CHINA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)
TABLE 91 CHINA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 92 CHINA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)
TABLE 93 INDIA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 94 INDIA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)
TABLE 95 INDIA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 96 INDIA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)
TABLE 97 AUSTRALIA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 98 AUSTRALIA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)
TABLE 99 AUSTRALIA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 100 AUSTRALIA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–2030 (USD MILLION)
TABLE 101 SOUTH KOREA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 102 SOUTH KOREA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018–2030 (USD MILLION)
TABLE 103 SOUTH KOREA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 104 SOUTH KOREA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018–

2030 (USD MILLION)
TABLE 105 REST OF ASIA PACIFIC: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106 REST OF ASIA PACIFIC: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 107 REST OF ASIA PACIFIC: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108 REST OF ASIA PACIFIC: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018-2030 (USD MILLION)
TABLE 109 MIDDLE EAST & AFRICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY REGION, 2018-2030 (USD MILLION)
TABLE 110 MIDDLE EAST & AFRICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111 MIDDLE EAST & AFRICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 112 MIDDLE EAST & AFRICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113 MIDDLE EAST & AFRICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018-2030 (USD MILLION)
TABLE 114 MIDDLE EAST: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 115 MIDDLE EAST: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 116 MIDDLE EAST: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117 MIDDLE EAST: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018-2030 (USD MILLION)
TABLE 118 AFRICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119 AFRICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 120 AFRICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121 AFRICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2018-2030 (USD MILLION)
TABLE 122 MAJOR MANUFACTURERS IN COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET
TABLE 123 MOST ACTIVE PLAYER IN COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET
TABLE 124 PRODUCT APPROVALS AND PRODUCT LAUNCHES
TABLE 125 PARTNERSHIP/COLLABORATION/INVESTMENT
TABLE 126 BUSINESS EXPANSIONS/AGREEMENTS
TABLE 127 MERGERS & ACQUISITIONS
TABLE 128 D CUBE ANALYTICS: PRODUCTS OFFERED
TABLE 129 GENPACT: PRODUCTS OFFERED
TABLE 130 AUROCHS: PRODUCTS OFFERED
TABLE 131 AUROCHS: KEY DEVELOPMENTS
TABLE 132 THEMATHCOMPANY: PRODUCTS OFFERED
TABLE 133 THEMATHCOMPANY: KEY DEVELOPMENTS
TABLE 134 AXTRIA: PRODUCTS OFFERED
TABLE 135 AXTRIA: KEY DEVELOPMENTS
TABLE 136 ZS: PRODUCTS OFFERED
TABLE 137 ZS: KEY DEVELOPMENTS
TABLE 138 INDEGENE: PRODUCTS OFFERED
TABLE 139 INDEGENE: KEY DEVELOPMENTS
TABLE 140 TIGER ANALYTICS: PRODUCTS OFFERED
TABLE 141 BEGHOU CONSULTING: PRODUCTS OFFERED
TABLE 142 BEGHOU CONSULTING: KEY DEVELOPMENTS
TABLE 143 TACT.AI TECHNOLOGIES, INC.: PRODUCTS OFFERED
TABLE 144 TACT.AI TECHNOLOGIES, INC.: KEY DEVELOPMENTS
TABLE 145 ANAPLAN, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 146 IBM: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 147 IBM: KEY DEVELOPMENTS
TABLE 148 COGNIZANT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 149 COGNIZANT: KEY DEVELOPMENTS
TABLE 150 ACCENTURE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 151 ACCENTURE: KEY DEVELOPMENTS
TABLE 152 MEDIDATA SOLUTIONS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 153 CITIUSTECH INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 154 PHARMAACE.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 155 FRACTAL ANALYTICS INC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 156 MU SIGMA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 157 WNS (HOLDINGS) LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 158 TATA CONSULTANCY SERVICES LIMITED.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 159 WIPRO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 160 VEEVA SYSTEM INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS – GLOBAL COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET
FIGURE 8 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY TYPE, 2023-2032 (USD MILLION)
FIGURE 9 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY COMPONENTS, 2023-2032 (USD MILLION)
FIGURE 10 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY APPLICATION, 2023-2032 (USD MILLION)

FIGURE 11 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY DEPLOYMENT, 2023-2032 (USD MILLION)
FIGURE 12 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY REGION 2023-2032 (USD MILLION)
FIGURE 13 GLOBAL: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET SHARE (%), BY REGION, 2021
FIGURE 14 AMERICAS: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY REGION 2023-2032 (USD MILLION)
FIGURE 15 NORTH AMERICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET SHARE (%), BY COUNTRY 2021
FIGURE 16 EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET, BY REGION 2023-2032 (USD MILLION)
FIGURE 17 WESTERN EUROPE: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET SHARE (%), BY COUNTRY 2021
FIGURE 18 ASIA PACIFIC COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET SHARE, BY COUNTRY 2023-2032 (USD MILLION)
FIGURE 19 ASIA PACIFIC: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET SHARE (%), BY COUNTRY, 2021
FIGURE 20 MIDDLE EAST & AFRICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET SHARE, BY REGION 2023-2032 (USD MILLION)
FIGURE 21 MIDDLE EAST & AFRICA: COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET SHARE (%), BY REGION, 2021
FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 23 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET
FIGURE 24 COMMERCIAL PHARMACEUTICAL ANALYTICS MARKET: COMPETITIVE LANDSCAPE
FIGURE 25 MAJOR PLAYERS SALES & OPERATING INCOME, 2021
FIGURE 26 MAJOR PLAYERS R&D EXPENDITURE, 2021
FIGURE 27 GENPACT: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 ANAPLAN, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 IBM: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 IBM: SWOT ANALYSIS
FIGURE 31 COGNIZANT: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 ACCENTURE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 ACCENTURE: SWOT ANALYSIS
FIGURE 34 MEDIDATA SOLUTIONS: FINANCIAL OVERVIEW
FIGURE 35 WNS (HOLDINGS) LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 WNS HOLDINGS LIMITED: SWOT ANALYSIS
FIGURE 37 TATA CONSULTANCY SERVICES LIMITED: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 TATA CONSULTANCY SERVICES LIMITED: SWOT ANALYSIS
FIGURE 39 WIPRO: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 WIPRO: SWOT ANALYSIS
FIGURE 41 VEEVA SYSTEM INC.: FINANCIAL OVERVIEW